FDA Distinguishing Medical Device Recalls from Medical Device Enhancements

标准简介

Distinguishing Medical Device Recalls from Medical Device Enhancements[附网盘链接]是Food And Drug Administration于不久之前发布的FDA标准,适用于United States。

标准截图

Distinguishing Medical Device Recalls from Medical Device Enhancements[附网盘链接]
Distinguishing Medical Device Recalls from Medical Device Enhancements[附网盘链接](截图)

 

标准文档说明

标准文档类型为Distinguishing Medical Device Recalls from Medical Device Enhancements[附网盘链接]高清PDF版本(文字版),标准文档内可进行搜索,可以复制原文,可粘贴。

标准部分原文

Distinguishing Medical Device Recalls from Medical Device Enhancements Guidance for Industry and Food and Drug Administration Staff This guidance represents the Food and Drug Administration's (FDA's) current thinking on this topic. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. You can use an alternative approach if the approach satisfies the requirements of the applicable statutes and regulations. If you want to discuss an alternative approach, contact the FDA staff responsible for implementing this guidance. If you cannot identify the appropriate FDA staff, call the appropriate number listed on the title page of this guidance. I. Introduction  

FDA defines a device recall by regulation as a firm's removal or correction of a marketed device that the Agency considers to be in violation of the laws that it administers and against which the agency would initiate legal action, e.g., seizure. 21 CFR 7.3(g). The key factor in distinguishing a medical device recall from an enhancement is the existence of a violation of the Federal Food, Drug, and Cosmetic Act (FD&C Act) [21 U.S.C. 360h] or associated regulations enforced by the Agency. Defects or performance failures of marketed medical devices can pose serious risks to public health. The recall process serves both to correct device defects and to notify users of potential risks and steps to minimize the impact of device failure or malfunction. Medical device recalls include voluntary recalls (covered by 21 CFR part 7, subpart C), either initiated by a firm on its own initiative or in response to a formal request from FDA, and mandatory recalls ordered by FDA under section 518 of 1

the FD&C Act and 21 CFR part 810. Typically, the medical device recall process under 21 CFR part 7, subpart C is initiated and coordinated by the firm. Subsequently the recall gets classified, monitored, and terminated by FDA district offices and the Center for Devices and Radiological Health (CDRH). FDA's guidance documents, including this guidance, do not establish legally enforceable responsibilities. Instead, guidances describe the Agency's current thinking on a topic and should be viewed only as recommendations, unless specific regulatory or statutory requirements are cited. The use of the word should in Agency guidances means that something is suggested or recommended, but not required. II. Background  

1

This guidance does not address mandatory recalls.

网盘链接

百度网盘:https://pan.baidu.com/s/11arwcvuIsTlH02CCCw5oQw
提取码:tv6t

【温馨提示】大资料ISO是提供信息发布的专业信息类网站,所有内容均由用户发布,不代表本站观点,本站亦不存储所涉及的文件及资料。如有【免费资料】以及【付费资料】,请用户根据自己的需求,自行判断是否需要获取。如有交易诈骗、内容侵权可发送邮件至kf@dzl100.com,我们审查后若发现情况属实,会立即对相关内容进行删除处理。

加载用时:27.9489 毫秒

相关评论

相关文章